GlobeNewsWire
26 Aug 2026, 12:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Daré Bioscience expects to commence prescription dispensing and initial product revenue for its compounded DARE to PLAY Sildenafil Cream in Q3 2026. — Direct timeline for revenue generation from a new product stream is a primary driver for biotech valuations.
+0.60A Phase 1 clinical study published in 'Menopause' found the proprietary 3.6% sildenafil cream was well tolerated with minimal systemic exposure in postmenopausal women. — Positive safety and pharmacokinetic data reduce clinical risk and validate the biological approach for further development.
+0.40The company is pursuing a dual-track strategy: launching a 503B compounded version immediately while pursuing a formal FDA 505(b)(2) regulatory pathway. — The compounded launch provides near-term cash flow, while the FDA path offers long-term competitive exclusivity and valuation upside.
+0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
Positive clinical study results published in a peer-reviewed journal and the upcoming launch of a compounded version of its Sildenafil Cream.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
2h ago
